Disclosure to Participants
Activity Title: Psychedelics in Psychiatry
For Enduring Activities Expiration date: Sept 1st, 2022
1. Successful completion this education program to earn contact hours requires:
- Attendance for at least 90% of the presentation.
- Completion/submission of evaluation form
- Successful completion of a post-test (must score 80 % or higher for credit)
2. Conflicts of Interest
The planners and presenters (C.J. Spotswood, RN the "EntheoNurse") disclose they do not have any relevant financial relationships with any commercial companies pertaining to this activity.
3. Commercial Company Support ☐ YES X NO
4. Joint Providership ☐ YES X NO
5. Approval Statement
This nursing continuing professional development activity was approved by Connecticut Nurses’ Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation
6. Desired Outcomes:
By the end of the presentation, participants will be able to:
- Define what a psychedelic substance is.
- Identify differences of MDMA, psilocybin, and LSD.
- Summarize the history of psychedelic use in psychiatry.
- Explain the projected outlook for psychedelic use in psychiatry for the future.
- Identify what the default mode network (DMN) is and how psychedelics can affect the DMN.
- Identify the 3 phases of psychedelic interventions.
- Identify the nurse’s role in psychedelic research and potential implications for practice in the future.